Processing Speed
The rate you take in new information, reach judgment on it, and formulate a response. (Hmm, that truck is driving erratically. I need to switch lanes.)
Neuroscience research has uncovered how malleable the brain is, even for people with genetic markers for dementia and Alzheimer's disease. New scientific evidence reveals how targeted lifestyle changes can benefit brain health both now and in the future.
Neurotrack's clinically-validated cognitive health solutions are designed to help individuals assess, monitor, and strengthen their brain health over time.
Neurotrack's team of neuroscientists, neuropsychologists and engineers have developed a clinically-validated suite of cognitive assessments that leverage eye-tracking technology. These digital assessments, taken regularly and over time, can serve as an early detection tool for identifying cognitive changes early.
Our technology uses the groundbreaking research of renowned neuroscientist and Neurotrack's co-founder, Dr. Stuart Zola, whose breakthrough clinical study on Alzheimer's Disease showed that eye movements, tracked through a camera, reveal important data about the state of our cognitive health and its potential for decline in the future.
Our assessments measure multiple cognitive domains (and the brain has many!) and provide a detailed report of one's cognitive condition.
The rate you take in new information, reach judgment on it, and formulate a response. (Hmm, that truck is driving erratically. I need to switch lanes.)
The ability to remember faces and places you've experienced before. It's a challenge for many of us, but particularly so as the brain ages.
The process by which a person learns an association between items. (ie. learning a new coworker's name, or learning that the sound of a siren means an emergency vehicle is near.
Related to Associative Learning, this is the ability to remember the relationship between items. (ie. smelling smoke and knowing that something must be burning on the stove, or walking down your street and knowing that this is where you live).
The FINGER study (The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) was a multi-year study of 1,200 adults at risk for cognitive decline. People who engaged in a multi-domain lifestyle intervention, including diet, exercise, and cognitive training, demonstrated improved cognitive performance.
This landmark study provides strong scientific evidence that targeted intervention can positively impact cognition over time – even in people who are at risk for decline. The FINGER study has been adapted on a global scale, with clinical studies taking place in multiple countries. Read more about World Wide FINGERS.
Our Cognitive Health Program is modeled after the multi-domain intervention that was proven to be effective in the FINGER study. Six lifestyle-related domains are included in our program, all of which are considered modifiable risk factors for dementia and Alzheimer's.
A year-long Phase 1 trial on the Neurotrack Cognitive Health Program demonstrated improvements in cognitive function, relief from depression, and a reduction in anxiety among older adults who were at-risk of cognitive impairment.
Neurotrack is always investing in its clinical research. In 2019, the company received a $3.3 million grant from the National Institute on Aging, a division of the U.S. National Institutes of Health, to conduct a Phase II randomized clinical trial to further validate Neurotrack’s Cognitive Health Program.
Currently, there is no cure for dementia-related diseases like Alzheimer's. Clinical trials in the past two decades have seen 146 failures with only 4 drugs approved for Alzheimer's treatment1. These FDA-approved drugs only treat the symptoms of the disease2. None of these drugs can slow or stop progression of the disease and symptoms often return over time.
So, what can you do?
It's not rocket science, but it is brain science. Neurotrack invests in and leverages the latest neuroscience research to deliver convenient, digital solutions to help businesses and individuals better manage their cognitive health for customers and themselves.
1. Stone, G. (2018). Researching Alzheimer’s medicines: Setbacks and stepping stones. Retrieved from Alzheimer’s Disease International website: https://www.alz.co.uk/sites/de...
2. Mayo Clinic. (2019, April 19). Alzheimer's: Drugs help manage symptoms. Retrieved from https://www.mayoclinic.org/dis...
Join Neurotrack in addressing the gap that exists in Alzheimer’s research today. We are offering an opportunity to researchers to use Neurotrack's digital cognitive assessment platform in dementia and Alzheimer's studies involving underrepresented populations. The application period is open through February 21, 2021.